Black Diamond rises as lung cancer drug meets main goal
03/12/2025 12:15
** Shares of precision oncology firm Black Diamond Therapeutics BDTX.O rise 3.8% to $3.58 premarket ** Co says its experimental cancer drug silevertinib met main goal with 60% tumor response and 86% brain response in 43 lung cancer patients with rare EGFR mutations ** EGFR is a protein that helps cells grow; mutations can drive cancer ** Separately, co says it plans to start a mid-stage trial of silevertinib in patients with glioblastoma, an aggressive form of brain cancer, in the first half of 2026 ** Up to last close, stock up 61% YTD (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))